In the recently concluded phase II HERTHENA-Lung01 (NCT04619004) study, HER3-DXd dramatically improved ORR in EGFR-mutant NSCLC patients, including activity against brain metastases [129]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.